In the interest of service and due to the continuing COVID-19 Pandemic, the effectivity of FDA Circular No. 2020-028 entitled “Reissuance of the Guidelines for the Registration of Drug Products Under Emergency Use (DEU) for the Coronavirus Disease 2019 (COVID-19)” is hereby extended until 12 September 2021, regardless of the level of the imposed quarantine restrictions due to COVID-19.
For the information and guidance of the public.
Attachment:-> FDA Circular No.2020-028-A